Abbvie Stock News

Wells Fargo & Company initiated coverage on shares of AbbVie (NYSE:ABBV) in a research report released on Wednesday morning, The Fly reports. The brokerage issued an overweight rating on the stock. Several other brokerages also recently weighed in on ABBV. Barclays upped their target price on shares of AbbVie from $112.00 to $118.00 and gave []

Nonprofit organization Direct Relief inaugurated a $277,000 solar energy project in Guánicas Fire Station, through a grant from biopharmaceutical company AbbVie, which donated $50 million for these types of projects. The project will allow for these first responders to continue serving the people even in the event of natural disasters that may affect primary services, []

Related Stocks: ABBV ,

Allergan will pay up to $200 million to resolve allegations made by New York state and two counties that it helped fuel the opioid crisis.

Plimoth Trust Co. LLC boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 3.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 30,463 shares of the companys stock after acquiring an additional 1,032 shares during the quarter. Plimoth Trust []

Morris Capital Advisors LLC cut its stake in AbbVie Inc. (NYSE:ABBV) by 4.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 25,454 shares of the companys stock after selling 1,065 shares during the quarter. AbbVie comprises about 2.2% of Morris Capital Advisors LLCs []

Farmers & Merchants Trust Co of Chambersburg PA trimmed its stake in AbbVie Inc. (NYSE:ABBV) by 1.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,743 shares of the companys stock after selling 130 shares during the period. Farmers & []

Pharmaceutical company AbbVie has settled a lawsuit from New York claiming the drugmaker helped fuel the opioid crisis in the state. The company has agreed to pay out $200 million. Read Full Article at RT.com

Jurors in a New York State court are expected to hear closing arguments Wednesday over whether drugmakers AbbVie Inc and Teva Pharmaceutical Industries Ltd fueled an opioid epidemic in the state, concluding a trial that has lasted more than five months.

AbbVie Inc. (NYSE:ABBV) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $122.42 and last traded at $120.90, with a volume of 195979 shares traded. The stock had previously closed at $118.85. Several equities analysts have recently issued reports on ABBV shares. SVB Leerink reaffirmed a []

Wall Street brokerages predict that AbbVie Inc. (NYSE:ABBV) will announce $15.06 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for AbbVies earnings, with the lowest sales estimate coming in at $15.02 billion and the highest estimate coming in at $15.11 billion. AbbVie posted sales of $13.86 []

Leukemia Therapeutics Market Snapshot: The Global Leukemia Therapeutics Market is expected to grow at a steady growth during the forecast period 2019-2029, Leukemia Therapeutics Market report offers insights into the latest trends. It summarizes key aspects of the market, with a

Total Clarity Wealth Management Inc. raised its stake in shares of AbbVie Inc. (NYSE:ABBV) by 3.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 6,033 shares of the companys stock after purchasing an additional 189 shares during the quarter. Total Clarity Wealth Management Inc.s []